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Charcot-Marie-Tooth type 2B (CMT2B) is clinically characterized by marked distal muscle weakness and wasting
and a high frequency of foot ulcers, infections, and amputations of the toes because of recurrent infections. CMT2B
maps to chromosome 3q13-q22.We refined the CMT2B locus to a 2.5-cM region and report twomissensemutations
(Leu129Phe and Val162Met) in the small GTP-ase late endosomal protein RAB7 which causes the CMT2B pheno-
type in three extended families and in three patients with a positive family history. The alignment of RAB7 orthologs
shows that both missense mutations target highly conserved amino acid residues. RAB7 is ubiquitously expressed,
and we found expression in sensory and motor neurons.
The inherited neuropathies of the peripheral nervous sys-
tem show considerable clinical and genetical heteroge-
neity (De Jonghe et al. 2000). Some forms, the ulcero-
mutilating neuropathies, are characterized by prominent
sensory loss, often complicated by severe infections, ar-
thropathy, and amputations (Auer-Grumbach et al., in
press). So far, two loci and one gene have been reported
for autosomal-dominant ulcero-mutilating neuropathies.
However, molecular genetic studies have demonstrated
that a third locus must exist (Auer-Grumbach et al. 2000b;
Bellone et al. 2002). Hereditary sensory neuropathy type
I (HSN I [MIM 162400]) maps to chromosome 9q22.1–
q22.3 and is caused by mutations in the serine palmi-
toyltransferase, long chain base subunit-1 (SPTLC1) gene
(Bejaoui et al. 2001; Dawkins et al. 2001). Charcot-
Marie-Tooth type 2B (CMT2B [MIM 600882]) or he-
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reditary motor and sensory neuropathy type IIB (HMSN
IIB) was assigned to chromosome 3q13–q22 in an Amer-
ican family (Kwon et al. 1995). CMT2B is clinically
characterized by marked distal muscle weakness and
wasting and a high frequency of foot ulcers, infections,
and amputations of the toes because of recurrent infec-
tions. CMT2B is mild to severe, with sensory loss and
all modalities equally affected. Spontaneous pain is ab-
sent. Motor deficit is often the first and most prominent
sign of the disease. The distal leg muscles are more af-
fected than the hand muscles. Nerve-conduction–
velocity studies indicate a primarily axonal neuropathy
that allows clinical diagnosis in asymptomatic individ-
uals (reviewed in Auer-Grumbach et al., in press).
We performed a molecular genetic study of three
families with an ulcero-mutilating phenotype who were
previously linked to the CMT2B locus: an American
family (CMT-195) (Kwon et al. 1995), a Scottish family
(CMT-90) (De Jonghe et al. 1997), and an Austrian
family (CMT-140) (Auer-Grumbach et al. 2000a). To
determine whether these families share a common dis-
ease haplotype, we analyzed 15 STR markers in the
CMT2B region. These markers included six new poly-
morphic STR markers (D3SCMT126A, D3SCMT126B,
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D3SCMT126C, D3SCMT126D, D3SCMT126F, and
D3SCMT126G), which we isolated using sequence in-
formation from public databases. For each marker, al-
leles associated with the ulcero-mutilating phenotype
were identified, and a disease haplotype was recon-
structed in each family (fig. 1). No common disease hap-
lotype was observed among families CMT-195, CMT-
90, and CMT-140, suggesting the absence of a genetic
relationship among these families with CMT2B. How-
ever, a common disease haplotype spanning seven STR
markers, D3S3584–D3SCMT126C, was shared between
the Austrian family CMT-140 and a small branch of
another Austrian multigenerational pedigree, CMT-126
(patients III-5, IV-2, IV-3, and V-1), originally excluded
from the CMT2B locus (Auer-Grumbach et al. 2000b;
fig. 1). The five remaining patients (III-1, III-2, III-3, III-
7, and IV-4) with a CMT phenotype in CMT-126 did
not share this haplotype. The haplotype frequency for
the shared disease haplotype in CMT-140 and part of
CMT-126 is and indicates that it is highly64.6# 10
unlikely that both families share by chance the same
alleles over a seven-marker interval. When examining
the pedigree of CMT-126, it seems that the linked hap-
lotype was married into the family by individual II-3.
According to the family information, person II-3 was
known to have a “strange gait,” but no clinical records
were registered.
In family CMT-140, we observed a recombination in
affected individuals V-5, V-6, V-7, and VI-1 between
STR markers D3S1589 and D3S3584, mapping the
CMT2B locus telomeric to D3S1589. The recombina-
tion in patients III-5, IV-2, IV-3, and V-1 of the CMT-
126 family mapped the CMT2B locus centromeric to
marker D3SCMT126D. These data refined the CMT2B
region to 2.5 cM, between D3S1589 and D3SCMT126D
(fig. 1). In the CMT2B locus, we selected three known
positional candidate genes for mutation analysis in the
families with CMT2B: ZNF9 (zinc finger protein 9),
ABTB1 (ankyrin repeat and BTB domain containing 1)
and RAB7 (small GTP-ase late endosomal protein RAB7)
(NCBI Map viewer). For each gene, we determined the
exon-intron boundaries of the candidate sequences by
BLAST searches against the HTGS (intronic primers se-
quences available on request). We sequenced all known
exons and intron-exon boundaries in the patients with
CMT2B and detected no disease-causing mutations in
ZNF9 or ABTB1. However, in exon 3 of RAB7, we ob-
served a c.385CrT transition (Leu129Phe) in all patients
of family CMT-140, which was also present in the patients
belonging to the small linked branch of family CMT-126
(fig. 2A). A second c.484GrA transition (Val162Met) in
exon 4 was observed in families CMT-195 and CMT-90
(fig. 2B). The missense mutations showed cosegregation
with the CMT2B phenotype in all pedigrees and were
absent from 200 control chromosomes.
It is interesting that the remaining patients of family
CMT-126 (III-1, III-2, III-3, III-7, and IV-4) did not have
the Leu129Phe mutation in RAB7. The fact that indi-
viduals III-5, IV-2, IV-3, and V-1 of family CMT-126
shared the same disease haplotype (fig. 1) and the same
c.385CrT (Leu129Phe) mutation as the patients in fam-
ily CMT-140 (fig. 2A), indicated a close familial rela-
tionship between CMT-140 and part of CMT-126, who
originated from the same Austrian province. In CMT-
126, we found no obvious differences in neurological
and electrophysiological findings between patients with
the Leu129Phe mutation and those without the RAB7
mutation, except that the phenotype was more severe in
the branch with the Leu129Phe mutation, including the
occurrence of ulcers and amputations. Also, the ulcero-
mutilating CMT phenotype of the remaining patients in
family CMT-126 is likely to be caused by a mutation in
another gene (since SPTLC1 was excluded; data not
shown) and further supports the presence of a third locus
for ulcero-mutilating neuropathies.
In addition to this study, we selected a set of 24 un-
related patients diagnosed with an HSN or ulcero-mu-
tilating CMT phenotype for mutation analysis of RAB7.
In three patients, two Austrian and one Belgian, we
observed Leu129Phe (HSN-15.1) once and Val162Met
twice (HSN-8.1 and PN-626.1). These three patients
with RAB7 mutations have a family history of CMT
and ulcero-mutilations, but the additional patients were
not cooperative for genetic studies. Haplotype analysis
confirmed that the Austrian patient HSN-15.1, with a
family history of CMT2B, shared the linked haplotype
with the Austrian families CMT-140 and part of CMT-
126. These findings indicate a founder effect for the
Leu129Phe mutation in families CMT-126, CMT-140,
and HSN-15.1. However, the Austrian (HSN-8.1) and
Belgian (PN-626.1) patients with the Val162Met mu-
tation do not share a common disease haplotype and
are not related to the Scottish CMT-90 and American
CMT-195 families (data not shown).
The alignment of RAB7 orthologs shows that both
missense mutations target highly conserved amino acid
residues (fig. 2C). The Val162Met mutation affects
a valine that is conserved among all species. The
Leu129Phe mutation is located next to a conserved GTP-
binding domain (NKID). The leucine residue at position
129 is not conserved in Arabidopsis and yeast.
Vitelli and coworkers (1996) reported expression of
two transcripts of 2.5 kb and 1.8 kb for the human
RAB7 gene in different cell types. The expression in-
formation of human RAB7 and mouse Rab7 in the Uni-
gene database suggests ubiquitous expression (Unigene
Clusters: Hs.356386 and Mm.4268). We found expres-
sion in all tested tissues; in human, high expression was
found in skeletal muscle (fig. 3A), and, in mouse, high
expression was found in liver, heart, and kidney (fig.
Figure 1 Haplotype analysis of chromosome 3q13-22 STR markers in families with CMT2B. Pedigrees of four families with an ulcero-
mutilating phenotype linked to the CMT2B locus: A, Austrian family CMT-140; B, Austrian family CMT-126; C, Scottish family CMT-90; and
D, American family CMT-195. Symbols: open diamondp unaffected; filled diamondp affected; half-filled diamondp probably affected (i.e.,
CMT-126 II-3); slashed diamond p deceased; arrow p recombination; box p disease-associated haplotype. Pedigree structure and sex are
disguised to preserve anonymity. The best genetic and physical order of STR markers is according to NCBI (GenBank/LocusLink). The six
newly developed STR markers (D3SCMT126A, D3SCMT126B, D3SCMT126C, D3SCMT126D, D3SCMT126F, and D3SCMT126G) are lo-
calized between D3S2324 and D3S1587. Genotypes are represented by allele sizes in base pairs, and 0-0 p failed genotype. The RAB7 gene
is located on the same contig (NT_005523) as markers D3SCMT126B and D3SCMT126C. For genotyping, fragment analysis was performed
on an ABI Prism3700 DNA Analyzer and processed with the ABI GENESCAN 3.5 and GENOTYPER 3.6 software (Perkin Elmer Applied
Biosystems).
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Figure 2 DNA and protein sequence analysis of RAB7. A, Electropherogram showing the c.385CrT sequence variation in part of exon
3, resulting in the Leu129Phe missense mutation in families CMT-140 and CMT-126 and patient HSN-15.1. B, Electropherogram of the
c.484GrA sequence variation in part of exon 4, resulting in the Val162Met missense mutation in families CMT-90 and CMT-195 and patients
HSN-8.1 and PN-626.1. The corresponding genomic sequence of a control person is shown below. DNA sequencing was performed using the
DYEnamic ET Terminator Cycle Sequencing Kit (Amersham Pharmacia Biotech), and the sequencing reactions were loaded on the ABI Prism3700
DNA Analyzer (Perkin Elmer Applied Biosystems). The data were collected and analyzed via the ABI DATA COLLECTION version 1.1 and
DNA SEQUENCING ANALYSIS version 3.6 software, respectively. C, ClustalW multiple protein alignment of the RAB7 orthologs of the
region surrounding the Leu129Phe and Val162Met mutations. RAB7 orthologs: Human (Homo sapiens), mouse (Mus musculus), rat (Rattus
norvegicus), fly (Drosophila melanogaster), slime mold (Dictyostelium discoideum), nematode (Caenorhabditis elegans), mouse-ear cress (Ar-
abidopsis thaliana), and baker’s yeast (Saccharomyces cerevisiae). The highly conserved motif involved in guanine nucleotide binding is boxed.
Both amino acid mutations are shaded and indicated by an arrow.
3B). PCR analysis of cDNA from E13 mouse dorsal root
ganglia and ventral horn showed expression of Rab7 in
sensory and motor neurons, respectively (fig. 3C).
RAB7 belongs to the Rab family of Ras-related GTP-
ases. These Rab proteins are essential for the regulation
of intracellular membrane trafficking. The Rab proteins
regulate vesicular transport through the recruitment of
specific effector or motor proteins and may have a role
in linking vesicles and target membranes to the cyto-
skeleton (Echard et al. 1998; Nielsen et al. 1999). RAB7
is involved in transport between late endosomes and ly-
sosomes, and recent studies demonstrate that the Rab7-
effector protein RILP (Rab interacting lysosomal pro-
tein) induces the recruitment of dynein-dynactin motors
and regulates transport toward the minus-end of micro-
tubules (Cantalupo et al. 2001; Jordens et al. 2001).
Expression of Rab7 dominant-negative artificial mutants
in mammalian cells inhibits lysosomal degradation and
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Figure 3 Expression analysis of RAB7. A, Human 12-lane Multiple Tissue Northern blot (Clontech) containing poly A RNA from adult
tissues: lane 1, brain; lane 2, heart; lane 3, skeletal muscle; lane 4, colon; lane 5, thymus; lane 6, spleen; lane 7, kidney; lane 8, liver; lane 9,
small intestine; lane 10, placenta; lane 11, lung; and lane 12, peripheral blood leukocyte. The probe used for hybridization is a cDNA fragment
of 800 bp, obtained from plasmid clones containing partial human RAB7 cDNA sequences (IMAGp956B0837, IMAGp956M0263, and IM-
AGp956M2246 [Resource Center of the German Human Genome Project]). B, Mouse multiple tissue northern blot containing poly A RNA
from adult tissues (Clontech): lane 1, heart; lane 2, brain; lane 3, spleen; lane 4, lung; lane 5, liver; lane 6, skeletal muscle; lane 7, kidney; and
lane 8, testis. The probe used for hybridization is a full-length mouse Rab7 cDNA cloned into the pCRII-TOPO vector (Invitrogen). The mouse
Rab7 cDNA was generated via RT-PCR and SMART RACE cDNA Amplification (Clontech) from mouse brain RNA. Both northern blots (A
and B) were also hybridized with a b-actin cDNA probe (Clontech) as a control for RNA loading (lower part of figure). C, PCR amplification
of a mouse Rab7 cDNA fragment of 854 bp: M, 100-bp size marker; C, Rab7 full-length cDNA cloned into pCRII-TOPO; VH, ventral horn
cDNA; DRG, dorsal root ganglia cDNA; C-, blanco. VH and DRG were isolated from 13-d-old mouse embryos, total RNA was extracted
using the Totally RNA Kit (Ambion), and RT-PCR was performed using the SMART PCR cDNA Synthesis Kit (Clontech). Mouse Rab7 cDNA
primers (MRAB7-2F p 5′-CTGACCAAGGAGGTGATGGT-3′ and MRAB7-2R p 5′-GAACAGTTCTCTCACTCTCC-3′) were used to PCR
amplify the Rab7 cDNA fragment of 854 bp in both neuron populations.
disperses lysosomes. One such mutant, rab7N125I, is
localized in the GTP-binding domain of Rab7 (Press et
al. 1998). In vitro studies, performed in hamster BHK
kidney cells, demonstrated that this mutant rab7N125I
protein exists preferentially in a nucleotide-free form and
has been shown to have a dominant-negative effect on
late endocytic transport (Press et al. 1998). In contrast,
in human fibroblasts overexpressing Rab7, late endo-
cytic vesicles accumulated in the perinuclear region,
probably because of an increased motility in the minus-
end direction of microtubules (Lebrand et al. 2002). Ov-
erexpression studies of wild-type Rab7 also demon-
strated that the Rab7 protein is involved in the Golgi
targeting of glycosphingolipids (Choudhury et al. 2002).
It is interesting that the SPTLC1 gene, mutated in pa-
tients with ulcero-mutilating HSN type I, is involved in
the biosynthesis of sphingolipids (Bejaoui et al. 2001;
Dawkins et al. 2001).
To date, 60 human RAB genes have been identified,
and the majority are likely to control highly specialized
functions in many cell types. Mutations in RAB genes
may, therefore, cause a wide range of inherited diseases.
In addition, there is evidence for alteration in RAB func-
tion in the pathogenesis of acquired diseases, such as
infection due to intracellular micro-organisms (Seabra
et al. 2002). It is unclear how dysfunction of RAB7
causes sensory and motor neuropathy in patients with
CMT2B. However, other Rab proteins are involved in
trafficking mechanisms associated with neurite out-
growth and polarized sorting in neurons (Tang 2001).
The RAB3A protein regulates neurotransmitter release
and other forms of regulated secretion (Geppert et al.
1997). The Rab23 protein is implicated in neural pat-
terning, as demonstrated in the mouse sonic hedgehog
signaling pathway (Eggenschwiler et al. 2001).
In conclusion, we report two missense mutations in the
RAB7 late endosomal protein as the cause for the ulcero-
mutilating inherited peripheral neuropathy CMT2B. It
will be a challenge to explain why mutations in such a
universally expressed protein as RAB7 lead to an axonal
pathology in CMT2B.
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